eV3 Solitaire™ Platinum Revascularization Device

国家: 新加坡

语言: 英文

来源: HSA (Health Sciences Authority)

可用日期:

COVIDIEN PRIVATE LIMITED

类:

Class D medical device

厂商:

Micro Therapeutics, Inc. d/b/a EV3 Neurovascular

治疗领域:

Neurology

疗效迹象:

The Solitaire™ Platinum Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset. The Solitaire™ Platinum Revascularization Device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients whoare ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

產品總結:

Device System Info:[Sterile Medical Device], EO sterilized; Models: Solitaire™ Platinum Revascularization Device - SFR3-4-20-10, Solitaire™ Platinum Revascularization Device - SFR3-4-40-10, Solitaire™ Platinum Revascularization Device - SFR3-6-20-10, Solitaire™ Platinum Revascularization Device - SFR3-6-40-10, Solitaire™ Platinum Revascularization Device - SFR3-4-20-05, Solitaire™ Platinum Revascularization Device - SFR3-6-24-06

授权日期:

2016-11-10